[go: up one dir, main page]

MX2009003738A - Diagnóstico y tratamiento de cáncer usando anticuerpo anti-ereg. - Google Patents

Diagnóstico y tratamiento de cáncer usando anticuerpo anti-ereg.

Info

Publication number
MX2009003738A
MX2009003738A MX2009003738A MX2009003738A MX2009003738A MX 2009003738 A MX2009003738 A MX 2009003738A MX 2009003738 A MX2009003738 A MX 2009003738A MX 2009003738 A MX2009003738 A MX 2009003738A MX 2009003738 A MX2009003738 A MX 2009003738A
Authority
MX
Mexico
Prior art keywords
ereg
cancer
diagnosis
treatment
cell expressing
Prior art date
Application number
MX2009003738A
Other languages
English (en)
Inventor
Hiroyuki Aburatani
Hirotaka Ito
Kenji Yoshida
Original Assignee
Forerunner Pharma Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forerunner Pharma Res Co Ltd filed Critical Forerunner Pharma Res Co Ltd
Publication of MX2009003738A publication Critical patent/MX2009003738A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G01N33/57557—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)

Abstract

Se describe un método para el diagnóstico de cáncer, el cual se caracteriza por detectar una proteína epiregulina (EREG). Se ha encontrado que la expresión de una EREG se mejora a una frecuencia muy alta en un nivel de gen o un nivel de proteína en cáncer gastrointestinal, adenocarcinoma pulmonar, cáncer pancreático, cáncer gástrico o cáncer renal. En el diagnóstico o tratamiento de cáncer, se utiliza un anticuerpo que reconoce la proteína EREG. También se describen una composición farmacéutica, un inhibidor de proliferación de célula y un agente anti-cáncer, cada uno comprendiendo un anticuerpo capaz de unirse a una EREG como un ingrediente activo. Además se describe un método para inducir citopatía en una célula que expresa EREG o inhibir la proliferación de una célula que expresa EREG, poniendo en contacto la célula que expresa EREG con un anticuerpo capaz de unirse a una EREG.
MX2009003738A 2006-10-12 2007-10-12 Diagnóstico y tratamiento de cáncer usando anticuerpo anti-ereg. MX2009003738A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006278819 2006-10-12
PCT/JP2007/069988 WO2008047723A1 (fr) 2006-10-12 2007-10-12 Diagnostic et traitement du cancer à l'aide d'un anticorps anti-ereg

Publications (1)

Publication Number Publication Date
MX2009003738A true MX2009003738A (es) 2009-07-17

Family

ID=39313954

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003738A MX2009003738A (es) 2006-10-12 2007-10-12 Diagnóstico y tratamiento de cáncer usando anticuerpo anti-ereg.

Country Status (16)

Country Link
US (1) US9017684B2 (es)
EP (1) EP2070548B1 (es)
JP (2) JP5687822B2 (es)
KR (1) KR101493779B1 (es)
CN (2) CN103396486A (es)
AU (1) AU2007312367B2 (es)
BR (1) BRPI0719202A2 (es)
CA (1) CA2665528C (es)
IL (2) IL197914A (es)
MX (1) MX2009003738A (es)
MY (1) MY162056A (es)
NO (1) NO20091842L (es)
NZ (2) NZ576855A (es)
RU (2) RU2537245C2 (es)
UA (1) UA106194C2 (es)
WO (1) WO2008047723A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009003738A (es) 2006-10-12 2009-07-17 Forerunner Pharma Res Co Ltd Diagnóstico y tratamiento de cáncer usando anticuerpo anti-ereg.
US8536310B2 (en) 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
US9631169B2 (en) 2008-06-05 2017-04-25 Invivo Sciences Inc. Three dimensional tissues for high-throughput assays
DK2406288T3 (en) 2009-03-10 2017-03-27 Baylor Res Inst ANTIGEN PRESENTING CELL-TARGETED VACCINES
EP2406286B1 (en) 2009-03-10 2016-05-18 Baylor Research Institute Anti-cd40 antibodies and uses thereof
EP2436397B1 (en) * 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
IT1397083B1 (it) * 2009-12-04 2012-12-28 Biouniversa Srl Marcatore biochimico serico
US11536713B2 (en) 2009-12-25 2022-12-27 Chugai Seiyaku Kabushiki Kaisha Method for searching and screening for target of anti-cancer agent using non-human animal model having NOG established cancer cell line transplanted therein
MX367345B (es) 2010-02-24 2019-08-15 Immunogen Inc Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos.
US9518988B2 (en) 2010-04-18 2016-12-13 Yeda Research And Development Co. Ltd. Antibodies and methods of using same for treating ErbB/ErbB ligands associated diseases
US11124773B2 (en) 2010-10-06 2021-09-21 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell population and method for production thereof
EP2637692A4 (en) 2010-11-12 2014-09-10 Scott & White Healthcare ANTIBODIES TO THE ENDOTHELIAL TUMOR MARKER 8
ES2865068T3 (es) 2011-01-14 2021-10-14 Univ California Anticuerpos terapéuticos contra la proteína ROR-1 y métodos para usarlos
MY186591A (en) 2011-04-01 2021-07-29 Immunogen Inc Methods for increasing efficacy of folri cancer therapy
AR085484A1 (es) 2011-04-06 2013-10-02 Lilly Co Eli ANTICUERPOS QUE SE UNEN A TGF-a Y EPIREGULINA
MX340498B (es) 2011-06-30 2016-07-11 Chugai Pharmaceutical Co Ltd Polipeptido heterodimerizado.
JP6077997B2 (ja) 2011-09-07 2017-02-08 中外製薬株式会社 癌幹細胞の分離
EP2772268B8 (en) 2011-10-28 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell-specific molecule
TWI593705B (zh) * 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
US9163090B2 (en) 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
CA2883222C (en) 2012-08-31 2021-12-14 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
JP6433297B2 (ja) 2012-12-27 2018-12-05 中外製薬株式会社 ヘテロ二量化ポリペプチド
AU2014236677B2 (en) * 2013-03-15 2018-07-05 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
US20140273031A1 (en) * 2013-03-15 2014-09-18 The Cleveland Clinic Foundation In-vitro method for monoclonal antibody production
JPWO2014208482A1 (ja) * 2013-06-24 2017-02-23 中外製薬株式会社 ヒト化抗Ｅｐｉｒｅｇｕｌｉｎ抗体を有効成分として含む腺癌以外の非小細胞肺癌の治療剤
HRP20211317T1 (hr) 2013-08-30 2021-11-26 Immunogen, Inc. Antitijela i analize za detekciju folat receptora 1
JP7037884B2 (ja) 2014-01-13 2022-03-17 ベイラー リサーチ インスティテュート Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
WO2015113169A1 (en) * 2014-02-03 2015-08-06 Cnj Holdings, Inc. Humanized beta-amyloid binding molecules and uses thereof
CN110526933B (zh) 2014-02-18 2022-09-09 赛威德医疗公司 生物素变体、链霉亲和素突变体以及它们的应用
JP6861418B2 (ja) 2015-09-02 2021-04-28 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド ヒトｔ細胞免疫グロブリン及びｉｔｉｍドメイン（ｔｉｇｉｔ）に特異的な抗体
IL257531B2 (en) 2015-09-17 2023-04-01 Immunogen Inc Medicinal compositions containing anti-folr1 immunoconjugates
JP7045069B2 (ja) 2016-11-25 2022-03-31 サヴィッド・セラピューティックス株式会社 クリアリングエージェント
WO2019048040A1 (en) 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
WO2023168087A1 (en) * 2022-03-04 2023-09-07 Yale University Methods and compositions for treating and preventing fibrosis
CN116041482B (zh) * 2022-09-29 2024-05-03 江汉大学 一种结构肽段的cDNA、结构肽段和制备方法及应用
WO2025198143A1 (ko) * 2024-03-22 2025-09-25 사회복지법인 삼성생명공익재단 에피레귤린 억제제를 포함하는 암 면역치료용 항암보조제 및 암 전이 억제용 조성물

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5190858A (en) 1989-02-01 1993-03-02 Oncogene Science, Inc. Monoclonal antibodies directed to epitopes of human transforming growth factor--α and uses thereof
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
DE69333823T2 (de) 1992-03-24 2006-05-04 Cambridge Antibody Technology Ltd., Melbourn Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5783417A (en) 1993-06-04 1998-07-21 Taisho Pharmaceutical Co., Ltd. Human-derived tumor cell growth inhibitors
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
WO1996002576A1 (en) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
ES2569919T3 (es) 1999-04-09 2016-05-13 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
GEP20104998B (en) 1999-06-25 2010-06-10 Genentech Inc Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer
PL218428B1 (pl) 2000-10-06 2014-12-31 Kyowa Hakko Kogyo Kk Komórka, sposoby wytwarzania przeciwciał, leki zawierające przeciwciała, komórka CHO i przeciwciało klasy IgG
CU22979A1 (es) * 2000-12-08 2004-09-09 Centro Inmunologia Molecular Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
US20030003097A1 (en) 2001-04-02 2003-01-02 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with GnTIII
US7750204B2 (en) 2002-06-05 2010-07-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing antibody
EP1600459A3 (en) * 2002-06-28 2005-12-07 Domantis Limited Ligand
ATE475708T1 (de) 2003-01-22 2010-08-15 Glycart Biotechnology Ag Fusionskonstrukte und deren verwendung zur produktion von antikörpern mit erhöhter fc rezeptor bindungsaffinität und effektorfunktion
EP1607404A4 (en) * 2003-03-14 2008-01-23 Taisho Pharmaceutical Co Ltd MONOCLONAL ANTIBODY AND HYBRIDOM THAT PRODUCES THIS
US7195764B2 (en) * 2003-04-14 2007-03-27 Arius Research Inc. Cancerous disease modifying antibodies
NZ548785A (en) * 2004-01-07 2011-08-26 Novartis Vaccines & Diagnostic M-CSF-Specific monoclonal antibody and uses thereof
EP1747284A4 (en) * 2004-02-06 2009-03-11 Wyeth Corp DIAGNOSIS AND THERAPEUTICS AGAINST CANCER
EP2208783A1 (en) 2004-12-22 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Method of producing an antibody using a cell in which the function of fucose transporter is inhibited
JP2008527978A (ja) 2005-01-11 2008-07-31 モレキュラー ロジックス，インコーポレイテッド Ｐａｎ−ＨＥＲアンタゴニストおよび使用方法
EP2281901B1 (en) * 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
MX2009003738A (es) 2006-10-12 2009-07-17 Forerunner Pharma Res Co Ltd Diagnóstico y tratamiento de cáncer usando anticuerpo anti-ereg.
EP2436397B1 (en) * 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
GB0909906D0 (en) 2009-06-09 2009-07-22 Affitech As Antibodies
GB0909904D0 (en) 2009-06-09 2009-07-22 Affitech As Product
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient

Also Published As

Publication number Publication date
CN103396486A (zh) 2013-11-20
EP2070548B1 (en) 2017-01-18
KR101493779B1 (ko) 2015-02-16
CA2665528C (en) 2018-01-23
JP5687822B2 (ja) 2015-03-25
US9017684B2 (en) 2015-04-28
JP5992480B2 (ja) 2016-09-14
EP2070548A1 (en) 2009-06-17
RU2537245C2 (ru) 2014-12-27
US20090324491A1 (en) 2009-12-31
NO20091842L (no) 2009-07-13
RU2014141151A (ru) 2016-05-10
NZ601022A (en) 2014-09-26
IL197914A (en) 2014-07-31
IL225386A0 (en) 2013-06-27
IL225386A (en) 2014-07-31
AU2007312367A1 (en) 2008-04-24
CN101594883B (zh) 2018-04-10
JP2015091796A (ja) 2015-05-14
JPWO2008047723A1 (ja) 2010-02-25
RU2009117669A (ru) 2010-11-20
AU2007312367B2 (en) 2012-09-06
RU2014141151A3 (es) 2018-07-18
KR20090079214A (ko) 2009-07-21
IL197914A0 (en) 2011-08-01
NZ576855A (en) 2012-08-31
UA106194C2 (ru) 2014-08-11
MY162056A (en) 2017-05-31
EP2070548A4 (en) 2010-09-01
CN101594883A (zh) 2009-12-02
CA2665528A1 (en) 2008-04-24
BRPI0719202A2 (pt) 2015-06-16
WO2008047723A1 (fr) 2008-04-24

Similar Documents

Publication Publication Date Title
MX2009003738A (es) Diagnóstico y tratamiento de cáncer usando anticuerpo anti-ereg.
AR125268A2 (es) Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CY1122555T1 (el) Στοχευμενες θεραπευτικες πρωτεϊνες συντηξης λυσωσομικων ενζυμων και χρησεις αυτων
EA201270019A1 (ru) Двуцепочечная рнк, включенная в липидный состав и мишенью которой является ген pcsk9
EA201690377A1 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
UY33826A (es) Proteínas de unión con dominios trivariables y sus usos
UA97506C2 (xx) Інгібітори полі(adp-рибозо)полімерази$ингибиторы поли(adp-рибозо)полимеразы
EA200870185A1 (ru) Комбинации ингибиторов ang2 и vegf
MX2012007684A (es) Modificacion covalente ligando dirigida de proteina.
EA201070421A1 (ru) Микрорибонуклеиновые кислоты
ATE450547T1 (de) Eml4-alk-fusionsgen
MX341866B (es) Metodo para usar expresion genica para determinar la probabilidad de un desenlace clinico de cancer renal.
BR112012010762A2 (pt) inibidores de prolil hidroxilalse
CY1112924T1 (el) Κυτταροδιαπερατοι αναστολεις της jnk-σηματοδοτικης πορειας μεταγωγης
EA201991409A3 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
EA201070292A1 (ru) Способ активирования регуляторных т-клеток
MX2019004487A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
DK2179035T3 (da) Modificeret bakteriofag omfattende et alfa/beta-sasp-(small acid-soluble spore protein)-gen
EA201790178A1 (ru) Пептиды, несущие маннозо-6-фосфат, слитые с лизосомальным ферментом
ATE505562T1 (de) Doppel-oligonukleotid- nukleinsäurenachweisverfahren
EA201691094A1 (ru) Получение антител для конъюгации из культур клеток cho
BR112014027905A2 (pt) anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico.
BR112014026440A2 (pt) assays, methods and apparatus for assessing rna disruption
AR084163A1 (es) Metodo para el diagnostico de un carcinoma y usos del mismo

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights